Case Report: Potassium Inadequacy

Context: An individual presents with symptoms compatible with chronic potassium insufficiency: palpitations, blood pressure at the border of hypertension, muscle weakness that fluctuates with exertion, occasional cramps. Contributing factors are multiple and vary between individuals: dietary intake often below the Adequate Intake; ongoing losses through sweat (heat, sustained physical activity), through the gut, through renal excretion driven by chronic sympathetic tone, caffeine, nicotine or diuretic use; and impaired intracellular retention when magnesium status is itself low. A blood test shows serum potassium within the reference range.

Problem: Serum potassium is homeostatically defended within a narrow band by renal, endocrine, and cellular mechanisms. The body will mobilise potassium from cells and bone to keep the serum value normal long after tissue stocks are meaningfully depleted. The test therefore does not measure what the clinician is trying to know. In the face of a symptomatic patient, a “normal” serum potassium is not a reassuring finding — it is a systematic false negative for the question of tissue depletion. Yet standard care treats the value as an authoritative rule-out and closes the file with generic dietary advice.

Physiological rights analysis: The failure is structural, not marginal. It is not that a threshold is poorly calibrated, nor that patients simply fail to eat enough fruit. It is that a diagnostic tool measuring a defended compartment is being used to answer a question about a different compartment — and used with the force of a definitive rule-out. The right at stake is not merely to the Adequate Intake; it is to a clinical approach that recognises the mismatch between serum and tissue and does not deny care on the strength of a test that cannot, by construction, detect the state in question. Population-level intake data (USDA/NHANES: median around 2500 mg per day for decades against AIs of 3400 mg for men and 2600 mg for women) illustrate the entry-side deficit at scale — but they leave uncovered the many individuals whose intake is adequate and whose tissue stock is nonetheless depleted by ongoing losses or by co-nutrient deficits. The physiological-rights argument holds at both scales: population and individual.

Consequences: Randomised trials establish that increasing potassium intake lowers blood pressure in a dose-dependent manner. Meta-analyses of prospective cohorts link a higher sodium-to-potassium ratio linearly to stroke incidence and cardiovascular mortality. Chronic tissue depletion is further associated with kidney stone formation and accelerated bone mineral loss. The invisibility of the deficit at the individual level — normal serum K, generic advice, no follow-up — allows preventable disease to accumulate silently across decades and across entire populations, without the diagnostic system ever registering that anything is wrong.

Proposed solution: Move from single-lab triage to a composite clinical assessment: symptoms, dietary intake, ongoing losses (heat, physical load, medications, stimulants, GI history), co-nutrient status (magnesium in particular), and a therapeutic trial of increased potassium intake where the picture is compatible. Alternative markers exist and should be used where relevant: red-blood-cell potassium, spot or 24-hour urinary potassium, and functional response to repletion. At population level, structural reformulation of the food environment — lowering the sodium-to-potassium ratio of processed foods, on the model of universal iodisation — remains a rights-based public-health lever. Supplementation with medical supervision is warranted where clinically justified and where dietary reach is insufficient. The core principle: the physiological right is to a stock that the body can draw on, not to the maintenance of a laboratory value that the body defends precisely by depleting that stock.